This retrospective investigation analyzed data from a substantial cohort of 589 patients treated over an 11-year period across two prominent regional medical centers in central China. The comprehensive dataset allowed for robust examination of various clinicopathological factors, incorporating demographic information alongside tumor-specific details, and crucially, a spectrum of nutritional and inflammatory markers. By leveraging these variables, the researchers sought to elucidate how preoperative NPS correlates with both disease-free survival (DFS) and overall survival (OS).

The Naples Prognostic Score is a composite index reflecting systemic inflammatory responses and nutritional status, parameters increasingly recognized for their significance in cancer progression. It integrates neutrophil-to-lymphocyte ratios, serum albumin, and levels of cholesterol among other factors, representing a multidimensional perspective on a patient’s biological resilience. Its predictive capacity has been explored in several malignancies, but its significance in OCSCC has, until now, remained under-evaluated.

Employing rigorous univariate and multivariate Cox regression analyses, the study identified several independent prognostic factors. These included surgical margin status, extranodal extension (ENE), the NPS itself, the age-adjusted Charlson Comorbidity Index (ACCI), and the American Joint Committee on Cancer (AJCC) staging. Notably, NPS emerged as a potent independent predictor for both DFS and OS, underlining its utility as a stratification tool in clinical practice.

The correlation between a higher NPS and poorer survival outcomes was particularly compelling. This relationship highlights the dual impact of systemic inflammation and nutritional deficits in promoting tumor aggressiveness and diminishing patient resilience after surgery. By quantifying this risk through NPS, clinicians may better identify those patients at greater likelihood of recurrence or mortality.

Another critical dimension of this study relates to the role of adjuvant radiotherapy in enhancing survival outcomes. Kaplan-Meier survival analyses demonstrated that patients with advanced-stage disease (AJCC stage III-IVb) and intermediate to high NPS (scores 1–4) derived significant survival benefits from postoperative radiotherapy. This nuanced insight can be transformative, as it suggests that NPS not only forecasts prognosis but also helps tailor adjuvant therapeutic strategies, potentially sparing lower-risk individuals from unnecessary radiation exposure.

Conversely, patients with early-stage tumors (AJCC stage I-II) or a zero NPS score did not show significant survival improvement when subjected to adjuvant radiotherapy. This raises important questions about overtreatment in this subgroup and reaffirms the need for personalized treatment regimens. The inclusion of NPS in treatment algorithms could optimize therapeutic efficacy and reduce morbidity associated with aggressive interventions.

The interplay of other prognostic markers, such as ECOG Performance Status and ACCI, alongside NPS, enhances the fidelity of survival predictions. ECOG Performance Status, assessing patient functional capacity, and ACCI, evaluating comorbidities, provide contextual understanding of patient resilience independent of tumor biology. Their inclusion strengthens prognostic models by addressing the holistic patient profile, an approach increasingly embraced in oncology.

This study’s methodological rigor, involving a large, well-characterized patient population and sophisticated statistical modeling, lends substantial credibility to its conclusions. The length and breadth of the data collection period spanning over a decade allow for meaningful long-term survival analysis, adding depth to the prognostic insights gleaned.

Emerging evidence from this work advocates for the integration of NPS assessments into routine preoperative evaluations. Such practice could facilitate stratified risk evaluation, guiding surgeons and oncologists in making informed decisions regarding the necessity and intensity of adjuvant therapies. It also opens avenues for closer postoperative surveillance in high-risk groups, potentially enabling timely interventions upon disease recurrence.

Moreover, the study propels forward the understanding of the biological mechanisms underlying OCSCC progression. Systemic inflammation, as captured by NPS components, is increasingly implicated in modulating the tumor microenvironment, enhancing angiogenesis, immune evasion, and metastatic potential. Nutritional status further impacts immune competence and wound healing, suggesting that interventions aimed at modifying these factors preoperatively might improve patient outcomes.

The practical implications of incorporating NPS are significant, particularly in regions where resource allocation and treatment personalization are critical. This score offers a cost-effective, readily accessible means of risk stratification, as it depends on routine laboratory parameters often available in most clinical settings.

Beyond its immediate clinical utility, the findings stimulate important questions for future research. Prospective studies validating NPS in diverse populations and investigating the potential benefits of nutritional and anti-inflammatory interventions tailored based on NPS are warranted. In addition, integrating NPS with emerging molecular and genetic biomarkers could refine prognostic models further.

The compelling evidence presented by Xu, Wu, and Cheng sets a new standard for preoperative oncological assessment in OCSCC. Their work exemplifies how combining systemic inflammatory markers with traditional clinical parameters yields powerful tools to predict patient trajectories and tailor therapies effectively.

In conclusion, the Naples Prognostic Score emerges as a vital prognostic indicator with significant implications for managing oral cavity squamous cell carcinoma. Its adoption in clinical workflows promises enhanced precision in prognostication and therapeutic decision-making, ultimately aiming to improve patient survival and quality of life.

Subject of Research: Prognostic value of the preoperative Naples Prognostic Score in predicting disease-free and overall survival in patients with oral cavity squamous cell carcinoma undergoing surgery.

Article Title: Prognostic significance of preoperative Naples prognostic score for disease-free and overall survival in oral cavity squamous cell carcinoma post-surgery

Article References:
Xu, XL., Wu, CC. & Cheng, H. Prognostic significance of preoperative Naples prognostic score for disease-free and overall survival in oral cavity squamous cell carcinoma post-surgery. BMC Cancer 25, 757 (2025). https://doi.org/10.1186/s12885-025-14146-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14146-4

The research was conducted retrospectively on a cohort of 171 patients diagnosed with advanced NSCLC who underwent combined immune checkpoint inhibitor (ICI) therapy and chemotherapy. The investigators meticulously gathered clinical data alongside peripheral blood inflammatory markers to construct predictive models that could serve as reliable biomarkers for therapy efficacy and prognosis. Their focus centered on the systemic inflammatory response, particularly examining the NLR, fibrinogen levels, and other hematologic indices as potential indicators of therapeutic success or failure.

Among patients receiving first-line ICI plus chemotherapy, the study identified a critical threshold for pre-treatment NLR: values exceeding 3.3 correlated strongly with diminished progression-free survival (PFS). Elevated fibrinogen levels (greater than 3.196 g/L) similarly signaled poorer treatment outcomes. These findings underscore the interplay between systemic inflammation and cancer progression, highlighting how an imbalanced immune milieu marked by neutrophilia relative to lymphocytes may foster an environment conducive to tumor resistance and progression.

Crucially, the researchers developed a composite prognostic score combining NLR and fibrinogen—termed the NLR-Fib (NF) score—which demonstrated superior predictive accuracy compared to programmed cell death ligand 1 (PD-L1) expression assessed from tumor biopsies. PD-L1 has traditionally been utilized as a biomarker to select candidates for immunotherapy, but its variability and limitations have prompted the search for alternative or complementary measures. The NF score, derived from routine blood tests, offers a noninvasive, cost-effective, and reproducible tool for risk stratification in clinical practice.

The study also delved into a subset of NSCLC patients harboring targetable oncogenic driver mutations and treated with ICI plus chemotherapy beyond the first line. Here, a slightly higher NLR threshold of 3.53 was indicative of worse therapeutic responses and independently predicted both progression-free and overall survival (OS). Interestingly, prior duration of tyrosine kinase inhibitor (TKI) therapy exceeding 12 months emerged as an independent favorable prognostic factor for overall survival. This observation suggests that sustained disease control with targeted agents before immunotherapy may prime tumors for better responsiveness.

Further complexity was added by the identification of other factors influencing outcomes in this patient group. Secondary mutations such as the epidermal growth factor receptor (EGFR) T790M variant were associated with reduced PFS, as were a platelet-to-lymphocyte ratio (PLR) above 196.81 and hypoalbuminemia with albumin levels below 40.25 g/L. These markers collectively reflect the tumor’s evolving biology and systemic host factors that potentially modulate therapeutic efficacy.

Building on these insights, the authors formulated another prognostic metric termed the NLR-TKI-PFS (NTP) score, incorporating NLR levels and prior TKI progression-free survival time. This score stratified patients into three distinct risk categories — favorable, intermediate, and poor — correlating with median OS of 21, 12, and 5.3 months, respectively. Such a tool holds promise for guiding personalized treatment decisions and counseling patients regarding their prognosis in advanced disease stages.

The impact of this study extends beyond its immediate clinical findings. It challenges the current reliance on tissue-based biomarkers like PD-L1, which are often hampered by tumor heterogeneity, sampling bias, and dynamic expression changes. By contrast, systemic inflammation markers measured through blood tests provide a holistic snapshot of the host-tumor interaction and can be serially monitored to adapt treatment strategies.

Moreover, the accessibility and cost-effectiveness of blood-based biomarkers ensure the applicability of these prognostic scores even in resource-limited settings. As immunotherapy revolutionizes oncology care worldwide, such practical tools are imperative to optimize patient outcomes, avoid unnecessary toxicities, and contain healthcare costs.

The biological rationale underpinning the prognostic significance of NLR and fibrinogen is grounded in their roles in cancer pathophysiology. Neutrophils promote tumor progression by secreting pro-angiogenic factors and immunosuppressive cytokines, while lymphocytes, particularly cytotoxic T cells, are critical for anti-tumor immunity. A high NLR thus reflects a state of immune dysregulation favoring tumor escape. Elevated fibrinogen, a key coagulation factor, is implicated in tumor metastasis and inflammatory processes, further aggravating disease progression.

Beyond the statistical associations, this study advocates for integrating inflammatory markers into comprehensive clinical algorithms. Such integration may improve patient selection for immunotherapy and inform the timing of therapeutic interventions, combining or sequencing agents to overcome resistance mechanisms.

Future directions informed by this work include prospective validation trials to confirm the robustness of the NF and NTP scores across diverse populations and treatment regimens. Additionally, research into mechanistic links between inflammation and immunotherapy response could unveil novel therapeutic targets, potentially allowing modulation of the inflammatory milieu to enhance treatment efficacy.

Importantly, this research touches upon the personalized medicine paradigm, where nuanced patient stratification transcends conventional histological and genetic classifications. By incorporating systemic factors reflective of the host-tumor ecosystem, clinicians can better predict clinical trajectories and tailor interventions accordingly.

In summary, the study published in BMC Cancer heralds a promising advance in the prognostication of advanced NSCLC patients receiving ICI plus chemotherapy. Through innovative use of simple hematologic parameters, it provides a window into the complex interplay between cancer, host immunity, and treatment response. These insights bear the potential to refine therapeutic precision, improve survival outcomes, and ultimately transform patient care paradigms in oncology.

Subject of Research: Prognostic biomarkers in advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article Title: Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article References:
Liao, S., Sun, H., Lu, H. et al. Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
BMC Cancer 25, 697 (2025). https://doi.org/10.1186/s12885-025-13811-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13811-y